Sinovac Biotech Ltd.

SVA

AGP8696W1045

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2019-02-22 pm EST			5-day change	1st Jan Change
6.47 ^USD	-0.31%		-.--%	-.--%

Jan. 18	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd.	CI
2023	Scientists see risk of lost opportunity for long COVID research in China	RE

Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021

April 29, 2022 at 05:24 pm EDT

Sinovac Biotech Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was USD 19,374.9 million compared to USD 510.62 million a year ago. Net income was USD 8,467.48 million compared to USD 110.37 million a year ago. Basic earnings per share from continuing operations was USD 85.2 compared to USD 1.06 a year ago. Diluted earnings per share from continuing operations was USD 74.27 compared to USD 0.97 a year ago.

Latest news about Sinovac Biotech Ltd.

Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd.	Jan. 17	CI
Scientists see risk of lost opportunity for long COVID research in China	Dec. 13	RE
Sinovac Biotech Ltd. Reports on the Clinical Trial Progress of Its Anti-Covid-19 Antibody Sa55 Injection	23-09-11	CI
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital made an offer to acquire 10.04% stake in Sinovac Biotech Ltd. for an offer per share of $0.03.	23-08-24	CI
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
China mRNA vaccine development jumps into high gear	23-01-31	RE
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-12-29	CI
BioNTech COVID-19 Vaccines Shipped to China From Germany	22-12-21	MT
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine	22-11-04	MT
Sinovac Varicella Vaccine Prequalified by WHO	22-11-03	CI
Indonesia approves first home-grown COVID vaccine for emergency use - media	22-09-28	RE
Sinovac Biotech Gets Chilean Health Regulator Approval to Start Clinical Trial for Its Omicron Containing COVID-19 Vaccine	22-09-06	MT
Sinovac Biotech Ltd. Announces the Chilean Public Health Institute Approve Phase II Clinical Trial for Its Inactivated Omicron Strain	22-09-06	CI
SINOVAC COVID-19 Vaccine Approves for Use in Children Above 6 months of Age in Hong Kong	22-08-03	CI
Sinovac Biotech Initiates Phase 3 Clinical Trial for Quadrivalent Influenza Vaccine in Chile	22-07-19	MT
Sinovac Biotech Ltd. Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile	22-07-19	CI
Sinovac Biotech Says Brazilian Health Regulator Approves COVID-19 Vaccine for Use in Children Ages 3 to 5	22-07-14	MT
Sinovac Biotech Ltd. Announces its COVID-19 Vaccine Authorized by Brazilian Health Regulatory Agency for Emergency Use in Kids Aged 3-5 in Brazil	22-07-14	CI
Sinovac Biotech Ltd. Joins Hands with University of Hong Kong Clinical Trials Centre Research Team and Gleneagles Hospital Hong Kong to Kick Off A Clinical Trial of an Omicron-Specific Inactivated Vaccine for Booster Use in Hong Kong, China	22-07-04	CI
Sinovac Biotech Secures Conditional Registration in South Africa for COVID-19 Vaccine	22-06-27	MT
Sinovac's COVID-19 vaccine conditionally registered in South Africa	22-06-25	RE
Sinovac Biotech Ltd. Announces South African Health Products Regulatory Authority Granted Conditional Registration to SINOVAC CoronaVac	22-06-25	CI
Sinovac Biotech Ltd. Polio Vaccine Prequalified by WHO	22-06-09	CI
Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-29	CI

Chart Sinovac Biotech Ltd.

Duration

Period

More charts

Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SINOVAC BIOTECH LTD.	-.--%	642M
CSL LIMITED	-4.55%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B